Insulet (NASDAQ:PODD) Given New $386.00 Price Target at Leerink Partners

Insulet (NASDAQ:PODD) had its target price lifted by equities researchers at Leerink Partners from $385.00 to $386.00 in a research report issued on Friday,MarketScreener reports. The brokerage currently has an “outperform” rating on the medical instruments supplier’s stock. Leerink Partners’ price target would indicate a potential upside of 23.37% from the company’s previous close.

A number of other analysts have also weighed in on the company. Truist Financial increased their price objective on Insulet from $365.00 to $390.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Piper Sandler increased their price target on shares of Insulet from $320.00 to $360.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Weiss Ratings restated a “hold (c)” rating on shares of Insulet in a research report on Wednesday, October 8th. Barclays raised their target price on Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Finally, Jefferies Financial Group upped their price target on Insulet from $375.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $377.85.

Insulet Stock Down 9.7%

Shares of NASDAQ PODD opened at $312.89 on Friday. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The business has a 50-day moving average of $322.43 and a 200-day moving average of $314.18. The firm has a market capitalization of $22.01 billion, a price-to-earnings ratio of 95.10, a PEG ratio of 2.64 and a beta of 1.39. Insulet has a 12 month low of $230.05 and a 12 month high of $354.88.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The business had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business’s quarterly revenue was up 29.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts expect that Insulet will post 3.92 earnings per share for the current fiscal year.

Insider Transactions at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares of the company’s stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.39% of the company’s stock.

Institutional Trading of Insulet

A number of institutional investors and hedge funds have recently bought and sold shares of PODD. Zions Bancorporation National Association UT purchased a new stake in shares of Insulet during the first quarter valued at approximately $26,000. SouthState Corp raised its stake in shares of Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 76 shares during the last quarter. True Wealth Design LLC raised its position in Insulet by 288.0% in the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 72 shares during the last quarter. Kozak & Associates Inc. bought a new position in Insulet during the 2nd quarter valued at about $32,000. Finally, Golden State Wealth Management LLC boosted its holdings in shares of Insulet by 202.9% during the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after acquiring an additional 69 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.